CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Apr. 30, 2014	Apr. 30, 2013	Apr. 30, 2014	Apr. 30, 2013
Revenues:
Clinical laboratory services	$ 14,542	$ 13,384	$ 43,250	$ 41,881
Product revenues	8,707	8,265	24,424	24,574
Royalty and license fee income	729	949	3,366	3,982
Total revenues	23,978	22,598	71,040	70,437
Operating expenses:
Cost of clinical laboratory services	9,784	9,331	28,785	28,466
Cost of product revenues	3,800	4,219	11,511	12,546
Research and development	849	989	2,498	2,968
Selling, general, and administrative	10,605	11,032	31,217	33,340
Provision for uncollectible accounts receivable	684	928	2,468	3,857
Legal fee expense	1,911	1,708	4,788	4,850
Legal settlements, net	(3,100)		(3,100)
Total operating expenses	24,533	28,207	78,167	86,027
Operating loss	(555)	(5,609)	(7,127)	(15,590)
Other income (expense):
Interest	(47)	(10)	(161)	(25)
Other	10	25	85	81
Foreign currency gain	144	(214)	460	119
Loss before income taxes	(448)	(5,808)	(6,743)	(15,415)
(Provision) benefit for income taxes	(7)	38	(65)	280
Net loss	$ (455)	$ (5,770)	$ (6,808)	$ (15,135)
Net loss per common share:
Basic and diluted (in Dollars per share)	$ (0.01)	$ (0.15)	$ (0.16)	$ (0.38)
Weighted average common shares outstanding:
Basic and diluted (in Shares)	43,243	39,553	42,062	39,381